Tamoxifen, a nonsteroidal antiestrogen, has been used as adjuvant treatment in patients with breast cancer since 1978. Since 1985, there have been reports that tamoxifen has a weak estrogenic effect on the female genital tract, particularly the endometrium, as manifested by the development of endometrial polyps, hyperplasia, and carcinoma (1). In addition, there have been two reports of carcinoma of the fallopian tube in patients receiving adjuvant tamoxifen for breast cancer (2,3). We describe bilateral atypical hyperplasia of the fallopian tube in two postmenopausal patients receiving long-term tamoxifen.
No takes yet. Share an insight, caveat, or question.
Pickel et al. (1998) studied this question.